Tina Turbin is a renowned Author and a Celiac and Gluten Free advocate. She researches and writes about the benefits of the Gluten-Free, Paleo-ish, Keto, and Lower Carb inclined diets while also supporting and promoting ethical companies she believes in. Tina’s award-winning site, PaleOmazing, houses many of her multi-award-winning recipes and research articles. She founded GlutenFreeHelp.info, voted #2 .info site in the world in 2009 out of over 6.7 million other .info sites, turning it over to her celiac daughter Miranda Jade Turbin in 2012. Tina does 1 on 1 private consulting for a Customized-Diet and Lifestyle Change, The Home Kitchen Ingredient’s Facelift and Restaurant Menu consulting. She is the CEO and Founder of TTAT, Inc. Founder of PaleOmazing.com, partner in two Los Angeles restaurants and co-owner of a café. Tina has released numerous award-winning eBooks, hundreds of articles, is a mother of three and also carries an additional title of award-winning children’s author of Danny the Dragon Meets Jimmy.
Celiac.com 11/30/2011 - Researchers have been talking about it for some time, raising the hopes of the celiac community: a drug to help relieve us from the harmful effects of gluten exposure. Celiac patients are closer than ever to having such a drug on the market, as Alvine Pharmaceuticals has announced that their drug ALV003 has shown promise in a clinical trial by reducing gluten-triggered harm in people with celiac disease.
Celiac disease is an autoimmune reaction triggered by exposure to gluten, a protein found in wheat, barley, and rye, that causes the immune system to attack the small intestine, interfering with the absorption of nutrients and leading to malnutrition and a variety of other symptoms. The disease currently has only one treatment, which is non-drug: the gluten-free diet. By eliminating gluten completely from the diet, most celiac patients can heal their small intestine. There is currently no other drug on the market that can help relieve the symptoms of celiac disease or the intestinal damage it can cause.
Now Alvine Pharmaceuticals, which is focused on developing biopharmaceuticals for autoimmune inflammatory diseases such as celiac disease, has reported favorable results for a trial with their drug ALV003, which was developed to lessen mucosal injury in the intestine caused by gluten exposure in well-controlled celiac patients.
A control group study was conducted that collected data from 34 celiac patients. After both the active drug group and placebo group ingested two grams of gluten on a daily basis for six weeks, "The group with the placebo reported higher incidence of 'non-serious adverse events' (code for GI symptoms)," Triumph Dining reported. "They also had significantly more mucosal injury in their small intestines, as measured by biopsy data."
ALV003 works by breaking down the gluten molecule into nontoxic parts. (Alvine Pharmaceuticals explains more specifically how the drug works on their website, AlvinePharma.com.) The drug is intended to help alleviate the gastrointestinal and other symptoms associated with cross-contamination, incorrect or misleading "gluten-free" labeling, and exposure to gluten caused by carelessness or imprudence. Even when celiac patients take care to maintain a strict gluten-free, it's difficult to stay completely away from gluten. That's why, according to coordinating investigator of the latest ALV003, Markku Maeki, M.D., chair and professor of pediatrics at the University of Tampere and Tampere University Hospital in Finland, "New non-dietary treatment options that can either eliminate, or meaningfully reduce the gluten present in an attempted gluten-free diet are needed."
Currently celiacs have no drug options to help alleviate their symptoms. "These results are groundbreaking," said Professor Maeki, "as they demonstrate for the first time, in a controlled clinical trial, that a drug has the potential to diminish gluten-induced injury in celiac disease patients."
According to Triumph Dining, "After Phase 3 trials, so long as
results remain promising, ALV003 will enter Phase 2b trials soon; after
that come Phase 3 trials and (hopefully) submission to the FDA for
approval." The release of ALV003, should results remain favorable, will
no doubt bring relief to many members of the celiac community.